Dominika Gruszecka Joins Cannabis Science and Technology®’s Editorial Advisory Board
Cannabis Science and Technology® is pleased to announce the addition of Dominika Gruszecka to its editorial advisory board.
Cannabis Science and Technology® announces that Dominika Gruszecka will be joining its editorial advisory board (EAB) effective immediately.
Dominika Gruszecka
Gruszecka is the Food and Consumer Products Market Manager at Shimadzu Scientific Instruments. She received her B.Sc. degree in Chemistry and M.Sc. degree in Analytical Chemistry from the University of Waterloo in Canada under the supervision of Dr. Janusz Pawliszyn.
Gruszecka's background involves anthropogenic contaminant testing in food using a variety of sample introduction techniques to gas chromatography–mass spectrometry (GC–MS), including static and dynamic headspace, and solid phase microextraction (SPME). She started at Shimadzu Scientific Instruments as a product specialist where she broadened the flavor and fragrance portfolio for the GC and GC–MS product line prior to her current role.
When asked what she is most excited about in the cannabis market, Gruszecka responded: “Being from a flavor and fragrance background through previous work with the GCMS team at Shimadzu, the projects we and our partners are working on for terpene profiling are the most exciting to me. Expanding beyond our safety and potency testing capabilities, having a way to assess products for extra functional components can be really impactful when targeting their expression.”
Cannabis Science and Technology's editorial advisory board is a group of distinguished individuals assembled to help the publication fulfill its editorial mission to educate the legal cannabis industry about the science and technology of analytical testing and quality control. The official charter of the advisory board for Cannabis Science and Technology is to support the publication in identifying the most significant developments in the cannabis science field, and in ensuring the relevance and technical accuracy of our content.
“Shimadzu is a long-standing thought-leader and innovative company when it comes to the analytical science and cannabis markets,” said Stephanie Shaffer, Group Publisher of Cannabis Science and Technology. “We value our relationship with them and are thrilled to have a member of their team contribute to our editorial mission through the editorial advisory board.”
Welcome to the board, Dominika Gruszecka!
For a complete list of the Cannabis Science and Technology® Editorial Advisory Board please visit: www.cannabissciencetech.com/cannabis-science-and-technology-editorial-advisory-board. If anyone in the industry is interested in learning more about the editotorial advisory board or possibly joining, please contact our Group Editorial Director, Meg L’Heureux, at mlheureux@mjhlifescience.com.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
